Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke.[1][2]

This drug was developed by GlaxoSmithKline.

References

  1. ^ "Refanezumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association..
  2. ^ Cramer SC, Enney LA, Russell CK, Simeoni M, Thompson TR (March 2017). "Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients". Stroke. 48 (3): 692–698. doi:10.1161/STROKEAHA.116.014517. PMC 5325241. PMID 28228578.
Allikas: https://en.wikipedia.org/wiki/Refanezumab
No tags for this post.